Governance Dianthus Therapeutics, Inc.

DNTH

US2528281080

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 2024-09-06			5-day change	1st Jan Change
26.62 ^USD	-4.86%		-7.67%	+155.96%

Aug. 09	Wedbush Adjusts Dianthus Therapeutics' PT to $36 From $38, Keeps Outperform Rating	MT
Aug. 08	Dianthus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

Executive Committee: Dianthus Therapeutics, Inc.

Manager

Positions heldSince

Marino Garcia

57 year

Chief Executive Officer	2023-09-10
President	2023-09-10

Rashieda Gluck

Chief Tech/Sci/R&D Officer

2023-09-10

Jeffrey Stavenhagen

Chief Tech/Sci/R&D Officer

2023-11-28

Sankalp Gokhale

Chief Tech/Sci/R&D Officer

2023-09-10

Angela Norton

Chief Tech/Sci/R&D Officer

2023-09-10

Scott Nogi

Chief Operating Officer

2023-09-10

Judson Taylor

Chief Tech/Sci/R&D Officer

2023-09-10

Debra Segal

General Counsel

2023-09-10

Kristina Maximenko

Human Resources Officer

2023-09-10

Edward Carr

55 year

Comptroller/Controller/Auditor

2023-09-10

Adam Veness

38 year

General Counsel	2023-09-10
Corporate Secretary	2023-09-10

Simrat Randhawa

56 year

Chief Tech/Sci/R&D Officer

2023-09-10

Ryan Savitz

35 year

Director of Finance/CFO	2023-09-10
Treasurer	-

Jennifer Ruff

Investor Relations Contact

2023-11-28

Composition of the Board of Directors: Dianthus Therapeutics, Inc.

Director

CommitteesSince

Lonnie Moulder

66 year

Compensation Committee	2023-09-10
Governance Committee Chair	2018-12-31
Nominating Committee Chair	2018-12-31
Governance Committee	2023-09-10
Nominating Committee	2023-09-10

Alison Lawton

63 year

Audit Committee
Governance Committee Chair	2023-09-10
Nominating Committee Chair	2023-09-10

Paula Soteropoulos

56 year

Compensation Committee Chair	2023-09-10
Audit Committee	2023-09-10

Anne McGeorge

63 year

Audit Committee Chair	2023-09-10
Compensation Committee	2021-11-11

Tomas Kiselak

38 year

Compensation Committee	2023-09-10
Nominating Committee	2021-05-31

Lei Meng

52 year

Governance Committee	2023-09-10
Nominating Committee	2023-09-10

Jonathan Violin

48 year

Director/Board Member

2023-09-10

Marino Garcia

57 year

Director/Board Member

2023-09-10

Latest Appointments: Dianthus Therapeutics, Inc.

Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc	Apr. 11	CI
Dianthus Therapeutics, Inc. Announces Executive Appointments	Nov. 29	CI

More news

Former Officers and Directors: Dianthus Therapeutics, Inc.

Insider

Positions heldSinceUntil

Stephen Mahoney

Chief Operating Officer	2020-10-31	2023-08-31
Director of Finance/CFO	2020-10-31	2023-08-31

Thomas Beetham

General Counsel	2021-05-31	2023-08-31
Corporate Secretary	2021-05-31	2023-08-31

Age distribution of managers

Parity Men Women

Male	15
Female	8

Of which Executive Committee

Male	10
Female	4

Of which Directors

Male	4
Female	4

ESG Refinitiv

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.

Employees

Sector

Biotechnology & Medical Research

Calendar

2024-09-11 - Baird Global Healthcare Conference

More about the company

Governance Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

Biotechnology & Medical Research

Executive Committee: Dianthus Therapeutics, Inc.

Composition of the Board of Directors: Dianthus Therapeutics, Inc.

Latest Appointments: Dianthus Therapeutics, Inc.

Former Officers and Directors: Dianthus Therapeutics, Inc.

Age distribution of managers

Parity Men Women

Company Profile